Insulet sees FY24 revenue growth 20%-21%

For the year ending December 31, 2024, the Company is raising its expected revenue growth to a range of 20% to 21%. Revenue growth ranges by product line are: Total Omnipod of 21% to 22%; U.S. Omnipod of 19% to 21%; International Omnipod of 25% to 27%; Drug Delivery of (10)% to (5)%